文献速递中医内科中药与中成药合理使用

口服EGCG通过调节Oatp1a5和Oct1转录水平降低自发性高血压大鼠肠道纳多洛尔吸收

Oral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats.
PubMed 文献 · Phytomedicine · 2021-06-11

本研究在自发性高血压大鼠(SHR)中探讨表没食子儿茶素没食子酸酯(EGCG)对纳多洛尔药代动力学及血压控制的影响。每日10 mg/kg EGCG预处理13天后,单次10 mg/kg纳多洛尔给药,结果显示EGCG使纳多洛尔Cmax和AUC分别降低53%和51%,并显著下调回肠Oatp1a5、P-gp、Oct1及肝脏P-gp、Oct1 mRNA水平。EGCG预处理组收缩压显著高于未预处理组,提示EGCG可能通过抑制肠道转运体减少纳多洛尔吸收,导致血压控制不佳。

要点

  • EGCG预处理使SHR的纳多洛尔Cmax和AUC分别降低53%和51%。
  • EGCG显著下调回肠Oatp1a5、P-gp、Oct1及肝脏P-gp、Oct1 mRNA。
  • EGCG预处理组收缩压显著高于未预处理组,提示血压控制恶化。

核心结论

  • EGCG暴露可降低纳多洛尔生物利用度,导致血压控制不佳和心血管事件风险升高。
  • 纳多洛尔生物利用度降低与回肠Oatp1a5和Oct1 mRNA下调相关,进而导致吸收减少。

研究设计与样本

  • 雄性自发性高血压大鼠(SHR)每日灌胃EGCG 10 mg/kg体重,连续13天。
  • 第14天末次EGCG给药30分钟后单次灌胃纳多洛尔10 mg/kg体重。
  • 给药后6小时和22小时测量收缩压(SBP),采用HPLC测定血浆和尿中纳多洛尔浓度,非房室分析药代参数,实时PCR测定肝脏和回肠Oatp1a5、P-gp、Oct1 mRNA表达。

主要发现

  • EGCG预处理组SBP显著高于未预处理但接受纳多洛尔组。
  • EGCG预处理使血浆纳多洛尔Cmax和AUC分别降低53%和51%。
  • 14天口服EGCG使回肠Oatp1a5、P-gp、Oct1 mRNA水平分别下调4.03、8.01和4.03倍;肝脏P-gp和Oct1 mRNA分别下调2.61和2.66倍。

临床怎么用

  • 高血压患者合用EGCG(如绿茶提取物)与纳多洛尔时,需警惕纳多洛尔吸收减少导致血压控制不佳。
  • 建议监测合用时的血压和纳多洛尔疗效,必要时调整剂量。

局限性

  • 研究仅在大鼠模型中进行,结论需临床研究验证。
  • 未涉及其他β受体阻滞剂或不同剂量EGCG的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concurrent use of epigallocatechin-3-gallate (EGCG) and medication may lead to botanical-drug interactions, subsequently therapeutic failure or drug toxicity. It has been reported that EGCG reduces plasma nadolol bioavailability in normotensive models. Nevertheless, evidence on the effects of EGCG on hypertensive model, and the possible underlying mechanism have not been elucidated. OBJECTIVES: This study aims (i) to investigate the effects of EGCG on nadolol pharmacokinetics (maximum plasma concentration, time to achieve maximum concentration, area under the time-plasma concentration curve, plasma half-life and total clearance) and subsequently its impact on blood pressure control; and (ii) to identify transcriptional regulatory roles of EGCG on the nadolol intestinal and hepatic drug-transporters in SHR. METHODS: Male SHR were pre-treated with a daily dose of EGCG (10 mg/kg body weight, i.g.) for 13 days. On day-14, a single dose of nadolol (10 mg/kg body weight) was given to the rats 30 min after the last dose of EGCG administration. Systolic blood pressure (SBP) was measured at 6-h and 22-h post-nadolol administration. Plasma and urinary nadolol concentrations were quantified using high-performance liquid chromatography, and pharmacokinetic parameters were analyzed by using non-compartmental analysis. Hepatic and ileal Oatp1a5, P-gp, and Oct1 mRNA expressions were determined by real-time PCR. RESULTS: SBP of SHR pre-treated with EGCG and received nadolol was significantly higher than those which were not pre-treated with EGCG but received nadolol. Pre-treatment of EGCG resulted in a marked reduction of plasma nadolol maximum concentration (Cmax) and area under the time-plasma concentration curve (AUC) by 53% and 51% compared to its control. The 14-day treatment with oral EGCG led to a significant downregulation of mRNA levels of ileal Oatp1a5, P-gp, and Oct1 genes by 4.03-, 8.01- and 4.03-fold; and hepatic P-gp, and Oct1 genes by 2.61- and 2.66-fold. CONCLUSION: These data concluded that exposure to EGCG could lead to reduced nadolol bioavailability and therefore, uncontrolled raised blood pressure and higher risks of cardiovascular events. Our data suggest that the reduced nadolol bioavailability is associated with the downregulation of ileal Oatp1a5 and Oct1 mRNA levels that subsequently lead to poor absorption of nadolol to the systemic circulation.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Tan HJ, Ling WC, Chua AL, et al. Oral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats. Phytomedicine. 2021. PMID: 34303263. doi:10.1016/j.phymed.2021.153623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。